Even If You Missed the Event, You Can Still Gain Access
Last month, the Association for Accessible Medicines held our third annual GRx+Biosims conference—the premier scientific and regulatory event for the U.S. generics and biosimilars industry. For the first time, the conference took place virtually, to minimize spread of COVID-19.
GRx+Biosims is one of the central gatherings for everyone in the industry, said Sarah Yim, Director, Office of Therapeutic Biologics and Biosimilars at FDA, who gave an inspirational talk connecting her combat experience and the biosimilars frontier.
I enjoyed the meeting tremendously and learned a lot. Janvi Patel, of Ironshore A Liberty Mutual Company, said. GRx+Biosims was
very structured, with great content and great networking opportunities.
The three-day conference featured leaders from across the health care sectors, with extensive FDA participation, including remarks from Commissioner Stephen Hahn.
Health and Human Services Secretary Alex Azar reminded attendees,
Your work is essential to ensuring that Americans get the quality care they need, and the better health they deserve.
If you are one of the more than 400 industry professionals who attended the virtual GRx+Biosims, please take the survey and let us know what you thought. Surveys are due December 31, so please act soon. Responses have been enthusiastic, with many participants saying they were able to
be in two places at once thanks to the virtual format—that is, they could attend multiple sessions that would normally have occurred simultaneously. The virtual Expo Booth made business-to-business interactions easier than ever.
AAM Director, Meetings and Marketing, Jen Soup noted,
Attendees really enjoyed the fact that with so many concurrent sessions, they were able to go back later and watch additional sessions. A huge benefit which would have not been possible in-person. It was essential for us to adopt this new virtual experience to keep the industry abreast on the latest information about U.S. generics and biosimilars.
Suzett Perry, Douglas Pharmaceuticals (New Zealand) said,
It is great that we will have access to all conference videos and materials for the next several months. This gives me an opportunity to re-watch presentations, as well as listen to all others that I could not attend. Hence, great value for the money. I took advantage of the Health & Fitness feature and did a meditation session during one of the breaks.
The sessions with Paula Lay of Yogini Melbourne were just some of the ways participants could relax between keynote speakers and learning tracks.
Whether you registered already or plan on taking advantage of the special offer to register for On-Demand Access, GRx+Biosims has what you need to comprehend the generics and biosimilars landscape in the year ahead. With 11 keynotes, 22 Learning Track sessions, 20 Q&A sessions and a 4-session Complex Workshop, there is a tremendous amount of useful content available.
- AAM CEO Dan Leonard moderating a special panel on treating COVID-19, featuring former FDA commissioner Scott Gottlieb, Alexandra Pratt (MedStar Washington Hospital Center) and Rob Brenner (Virginia’s Valley Health System)
- David Gaugh, AAM Senior Vice President, Sciences & Regulatory Affairs moderating a panel on Quality Management Maturity System with John Darby (Lachman Consultant Services), Vipul Doshi (Zydus Pharmaceuticals) and Ranjana Pathak (Cipla).
- IQVIA’s Doug Long delivering a presentation titled
Global and U.S. Generics and Biosimilars: Trends, Issues and Outlook
Organizing a virtual event helped the AAM events team improve future events, whether they are in-person or online. Access! 2021, scheduled for late summer, will incorporate many added features for even better networking and learning. Join the mailing list to stay up to date.
GRx+Biosims 2020 Sponsors
We are grateful to all the sponsors that made GRx+Biosims 2020 virtual conference a success.
By Erica Klinger, AAM Marketing Director